Ctrl K
Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -17.50 | — | — | — | — | — | 6.14 | — | — | — | — | — | — | — | — | 1.21 | — | 51.27 | 5.09 | 28.79 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -95.8% | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 417.18 | 731.62 | 752.78 | 1177.70 | 1471.02 | 2039.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -71.6% | -64.1% | — | — | — | — | |
| P/B Ratio | 12.85 | 6.05 | 2.21 | 5.97 | 3.49 | 2.89 | 2.40 | 4.65 | — | — | 7.72 | 3.34 | 1.16 | 1.18 | 0.98 | 1.08 | 1.74 | 1.55 | 2.29 | 2.84 | 4.01 |
| — | +109.6% | -7.6% | +28.4% | — | — | -68.9% | +39.2% | — | — | +683.6% | +208.3% | -33.6% | -23.8% | -57.0% | -61.9% | -56.6% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | 3.18 | — | — | — | — | — | — | — | — | — | — | — | — | 15.61 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +101.9% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -26132.3% | -28648.4% | -28235.5% | -28987.1% | -24967.7% | -25900.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -4.7% | -10.6% | -65.1% | -93.0% | -26.4% | -246.4% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -16396.8% | -28025.8% | -13383.9% | -2819.4% | 5148.4% | -52135.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -418.5% | +46.2% | +75.7% | +80.5% | +115.2% | -812.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.6% | -29.5% | -9.3% | -44.7% | -13.2% | -5.8% | 10.5% | -55.1% | — | — | -87.8% | -62.0% | -31.4% | -27.3% | -20.1% | -10.2% | -15.5% | -6.7% | -1.4% | 2.5% | -46.9% |
| — | -406.3% | -189.1% | +18.9% | — | — | +111.9% | +11.2% | — | — | -336.1% | -509.3% | -102.5% | -307.5% | -1373.2% | -505.5% | +67.0% | +94.6% | +93.4% | — | — | |
| ROA | -32.9% | -19.0% | -5.4% | -27.0% | -11.3% | -4.8% | 7.3% | -21.9% | -44.4% | -77.1% | -22.5% | -24.2% | -15.5% | -15.3% | -12.1% | -6.2% | -9.7% | -4.3% | -0.9% | 1.7% | -25.5% |
| — | -299.3% | -174.4% | -23.0% | +74.5% | +93.8% | +132.3% | +9.3% | -186.0% | -404.9% | -86.8% | -289.0% | -59.2% | -258.5% | -1217.0% | -460.6% | +61.8% | +91.8% | +92.5% | +106.3% | — | |
| ROIC | — | — | — | — | — | — | — | — | — | — | -820.3% | -533.0% | -297.5% | -296.9% | -397.1% | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | -106.6% | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.39 | 0.01 | 0.04 | 0.08 | 0.09 | 0.15 | 0.20 | — | — | 3.53 | 1.79 | 0.99 | 0.74 | 0.57 | 0.48 | 0.44 | 0.38 | 0.36 | 0.01 | 0.01 |
| — | +324.6% | -91.1% | -81.9% | — | — | -95.9% | -88.6% | — | — | +513.6% | +273.8% | +126.1% | +95.1% | +60.8% | +5373.0% | +4994.3% | +328.6% | +697.9% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.31 | 16.09 | 28.05 | 13.31 | 8.25 | 7.04 | 4.64 | 2.77 | 1.18 | 1.62 | 2.00 | 2.59 | 4.37 | 6.54 | 11.82 | 12.81 | 13.41 | 14.86 | 17.48 | 15.84 | 20.68 |
| — | +128.6% | +504.3% | +381.1% | +596.3% | +333.5% | +131.5% | +6.6% | -72.9% | -75.2% | -83.0% | -79.8% | -67.4% | -56.0% | -32.4% | -19.1% | -35.2% | +173.3% | +226.1% | +112.4% | — | |
| Quick Ratio | 13.31 | 16.09 | 28.05 | 13.31 | 8.25 | 7.04 | 4.64 | 2.77 | 1.18 | 1.62 | 2.00 | 2.59 | 4.37 | 6.54 | 11.82 | 12.81 | 13.41 | 14.86 | 17.48 | 15.84 | 20.68 |
| — | +128.6% | +504.3% | +381.1% | +596.3% | +333.5% | +131.5% | +6.6% | -72.9% | -75.2% | -83.0% | -79.8% | -67.4% | -56.0% | -32.4% | -19.1% | -35.2% | +173.3% | +226.1% | +112.4% | — | |
| Interest Coverage | -17.02 | -23.70 | -4.67 | -19.83 | -68.99 | -19.32 | 25.11 | -35.08 | -20.86 | -38.22 | -11.73 | -15.49 | -11.61 | -13.93 | -13.44 | — | -15.74 | -8.54 | -51.35 | 146.09 | -564.14 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CADL stock.
Candel Therapeutics, Inc.'s current P/E is -17.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Candel Therapeutics, Inc.'s business trajectory between earnings reports.